Instructions to authors and Information for readers
26 February 2018
Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis
Hannah C. Jeffery, Manjit K. Braitch, Chris Bagnall, James Hodson, Louisa E. Jeffery, Rebecca E. Wawman, Lin Lee Wong, Jane Birtwistle, Helen Bartlett, Ansgar W. Lohse, Gideon M. Hirschfield, Jessica Dyson, David Jones, Stefan G. Hubscher, Paul Klenerman, David H. Adams, Ye H. Oo – 26 February 2018 – Autoimmune hepatitis (AIH) is an immune‐mediated liver disease currently treated by immunosuppressive medications with significant side effects. Thus, novel mechanistic treatments are greatly needed.
Cover Image
26 February 2018
Hepatology Highlights
Russell Rosenblatt, Robert S. Brown, Saurabh Mukewar, Yecheskel Schneider, Robert E. Schwartz, Shirley Cohen‐Mekelburg, Clara Tow, Aleksey Novikov, Nicholas Russo, Zaid H. Tafesh, Vikas Gupta – 26 February 2018
Table of contents
26 February 2018
Notices
26 February 2018
Hepatology Highlights
Russell Rosenblatt, Robert S. Brown, Saurabh Mukewar, Yecheskel Schneider, Robert E. Schwartz, Shirley Cohen‐Mekelburg, Clara Tow, Aleksey Novikov, Nicholas Russo, Zaid H. Tafesh, Vikas Gupta – 26 February 2018
Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta‐analysis
Yao‐Yao Zhou, Xiao‐Dong Zhou, Sheng‐Jie Wu, Dan‐Hong Fan, Sven Poucke, Yong‐Ping Chen, Shen‐Wen Fu, Ming‐Hua Zheng – 26 February 2018 – Nonalcoholic fatty liver disease (NAFLD) is associated with an increased risk of atherosclerotic cardiovascular disease. In our meta‐analysis, we aimed to assess the correlation of NAFLD and four surrogate markers of subclinical atherosclerosis. PubMed, Embase, and the Cochrane Library were searched up until April 2017. Original studies investigating the association between NAFLD and subclinical atherosclerosis were included.
Impact of a first study of early transplantation in acute alcoholic hepatitis: Results of a nationwide survey in french liver transplantation programs
Teresa Maria Antonini, Olivier Guillaud, Jérôme Dumortier, Sébastien Dharancy, Faouzi Saliba, Philippe Mathurin, Jean‐Charles Duclos‐Vallée, Christophe Duvoux, for Groupe de Recherche Français en Greffe de Foie (GReF2) – 24 February 2018
Fibroblast growth factor 21 is an early predictor of acute‐on‐chronic liver failure in critically ill patients with cirrhosis
Astrid Ruiz‐Margáin, Alessandra Pohlmann, Patrick Ryan, Robert Schierwagen, Luis A. Chi‐Cervera, Christian Jansen, Osvely Mendez‐Guerrero, Nayelli C. Flores‐García, Jennifer Lehmann, Aldo Torre, Ricardo Ulises Macías‐Rodríguez, Jonel Trebicka – 24 February 2018 – Acute‐on‐chronic liver failure (ACLF) develops in acute decompensation (AD) of cirrhosis and shows high mortality. In critically ill patients, early diagnosis of ACLF could be important for therapeutic decisions (eg, renal replacement, artificial liver support, liver transplantation).